Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Status:
Completed

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

This is an open-label, multicenter, dose-escalation, safety, pharmacokinetics, and pharmacodynamics study.

Phase 1

Biogen